Researchers from the Project ALS Therapeutics Core at Columbia (the Core), in a groundbreaking collaborative effort with Ionis Pharmaceuticals, have developed a new tool for studying ALS mechanisms and therapies, as well as a novel approach for treating ALS caused by mutations…
“I was diagnosed with ALS in February 2020 after a frustrating year of searching for answers & even longer of progressing symptoms…”
“Our connections to ALS run deep & very personal. Our dad passed away from ALS and, of his nine children, five have been diagnosed…”
“My sister, Janet, was diagnosed with ALS about a year and a half ago. I was stunned…”
“My husband, Mickey, was diagnosed with ALS in 2001 at the age of 49…”
“Our family has a deep and multi-generational connection to ALS. Our mother succumbed to ALS in 1987. She was almost 33…”
Like Rebecca, we must be brave enough to hope. When 3-time Tony nominee Rebecca Luker was diagnosed with ALS in 2019, she and her husband
A mother’s love may be the most powerful force on earth. Consider this: When their young teenagers were diagnosed out of nowhere with a virulent
Project ALS Announces Research Advisory Board 2.0 Non-Profit ALS Research Leader Gathers a Diversity of Expertise to Guide Next-Phase Progress (New York, NY)
On Wednesday, Amylyx Pharmaceuticals announced that they are planning to file a New Drug Application—the formal submission for a drug to be approved by the
Prosetin is moving to Phase I clinical trials. View the recording of our live conversation with clinical trial specialist Jinsy Andrews, MD, MSc and regulatory
NEW MAILING ADDRESS
2585 Broadway, Suite 202
New York, NY 10025
Phone: (212) 420-7382
Email: [email protected]
